Iradimed (IRMD) AI Stock Analysis

• Market Cap: $998.14M
• Dividend Yield: 0.84%
• Average Volume (3M): 56.88K
• Price to Earnings (P/E): 48.7
• Beta (1Y): 0.80
• Revenue Growth: 11.73%
• EPS Growth: 10.27%
• Country: US
• Employees: 160
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.49
• Shares Outstanding: 12,720,002
• 10 Day Avg. Volume: 53,301
• 30 Day Avg. Volume: 56,877
• PEG Ratio: 3.08
• Price to Book (P/B): 8.03
• Price to Sales (P/S): 9.51
• P/FCF Ratio: 39.55
• Enterprise Value/Market Cap: 0.72
• Enterprise Value/Revenue: 9.20
• Enterprise Value/Gross Profit: 11.96
• Enterprise Value/Ebitda: 29.29
• 1Y Price Target: $72.00
• Price Target Upside: -8.25% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 81 Outperform
• Price Target: $90.00 ▲(14.69% Upside)

Iradimed's overall stock score is driven by strong financial performance and positive earnings call highlights, including record revenue and growth expectations. Technical analysis supports a bullish trend, though valuation metrics suggest caution due to a high P/E ratio. The company's robust financial position and positive outlook make it an attractive investment, despite some operational challenges.

Iradimed Business Overview & Revenue Model

Company Description

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.

How the Company Makes Money

Iradimed generates revenue primarily through the sale of its MRI-compatible infusion pumps and associated disposables. The company’s revenue model is centered around the direct sale of these medical devices to hospitals and healthcare facilities, which often require ongoing maintenance and support. Additionally, Iradimed benefits from recurring revenue through the sale of disposable components that accompany their infusion pumps. Strategic partnerships with healthcare providers and distributors, along with a focus on expanding their product line and entering new markets, further contribute to their earnings. The company also invests in research and development to innovate and enhance their product offerings, ensuring a competitive edge and sustained revenue growth.

Iradimed Financial Statement Overview

Summary

Iradimed demonstrates strong financial performance with robust revenue growth, high gross profit margins, and a solid balance sheet with minimal debt. Cash flow generation is consistent, although net profit margins and capital expenditures could be optimized further.

Income Statement

Iradimed has demonstrated robust revenue growth with a 41.0% increase from 2022 to 2023 and a further 14.0% increase in 2024. Gross profit margins have remained strong, averaging around 77% over recent periods. The company maintains healthy EBIT and EBITDA margins, showcasing strong operational efficiency and profitability. However, the net profit margin, while solid, indicates room for further optimization.

Balance Sheet

The balance sheet of Iradimed is very healthy, with a remarkably low debt-to-equity ratio, indicating minimal leverage risk. The equity ratio is strong, reflecting a robust balance of equity to total assets. ROE is impressive, showing efficient use of equity to generate profits. Overall, the company has a solid financial position with low liabilities relative to equity.

Cash Flow

Iradimed shows a positive cash flow trend, with stable free cash flow generation despite fluctuations in capital expenditures. The operating cash flow to net income ratio is strong, indicating efficient cash conversion from profits. The free cash flow to net income ratio is consistent, though recent capital expenditures have slightly impacted free cash flow growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	77.64M	73.24M	65.56M	53.30M	41.81M	31.72M
Gross Profit	59.75M	56.35M	50.16M	41.28M	32.05M	23.57M
EBITDA	24.39M	22.78M	20.80M	16.30M	11.22M	3.28M
Net Income	20.66M	19.23M	17.19M	12.83M	9.33M	1.37M
Balance Sheet
Total Assets	106.45M	98.33M	92.16M	85.51M	82.88M	71.07M
Cash, Cash Equivalents and Short-Term Investments	53.00M	52.23M	49.76M	57.96M	62.50M	51.98M
Total Debt	0.00	154.69K	2.04M	2.21M	2.48M	2.72M
Total Liabilities	12.15M	11.51M	20.74M	11.84M	10.71M	9.68M
Stockholders Equity	94.30M	86.82M	71.42M	73.67M	72.17M	61.38M
Cash Flow
Free Cash Flow	13.55M	17.62M	5.46M	8.17M	10.52M	5.18M
Operating Cash Flow	27.14M	25.62M	13.47M	10.04M	11.26M	5.82M
Investing Cash Flow	-13.81M	-8.82M	-8.01M	-1.37M	648.24K	246.97K
Financing Cash Flow	-8.87M	-14.34M	-13.66M	-12.71M	24.43K	522.48K

Iradimed Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 78.47
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRMD, the sentiment is Positive. The current price of 78.47 is above the 20-day moving average (MA) of 73.83, above the 50-day MA of 72.37, and above the 200-day MA of 60.52, indicating a bullish trend. The MACD of 1.66 indicates Negative momentum. The RSI at 64.33 is Neutral, neither overbought nor oversold. The STOCH value of 92.46 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IRMD.

Iradimed Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IRMD	81 Outperform	$998.14M	48.67	23.75%	0.84%	11.73%	10.27%
AXGN	69 Neutral	$836.05M	―	-4.48%	―	17.17%	72.68%
SIBN	55 Neutral	$668.25M	―	-14.18%	―	22.93%	43.83%
BVS	55 Neutral	$573.79M	―	-0.10%	―	5.08%	99.38%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IART	51 Neutral	$1.26B	―	-38.92%	―	3.53%	-2309.98%
OFIX	51 Neutral	$630.72M	―	-24.63%	―	4.84%	0.85%

Iradimed Corporate Events

Iradimed Appoints Joe Kiani as New Director

On August 27, 2025, Anthony Vuoto retired from his position as a director of Iradimed Corporation and as chairman of the Compensation Committee for personal reasons, without any disagreements with the company. Following his retirement, Joe Kiani, a renowned medical technology innovator, was appointed on September 2, 2025, to fill the vacancy, maintaining the board size at five directors. Kiani, recognized for his expertise and leadership in medical technology, will serve as a member of the Audit Committee and chairman of the Compensation Committee, contributing to Iradimed’s growth in the medical device sector.

The most recent analyst rating on (IRMD) stock is a Buy with a $81.00 price target. To see the full list of analyst forecasts on Iradimed stock, see the IRMD Stock Forecast page.

Iradimed Corp Reports Record Q2 2025 Results

Iradimed Corporation is a leading developer of MRI-compatible medical devices, specializing in non-magnetic intravenous infusion pump systems and patient vital signs monitoring systems. In its latest earnings report, Iradimed announced record revenue of $20.4 million for the second quarter of 2025, marking a 14% increase from the previous year. The company also reported a GAAP diluted EPS of $0.45, up 18% year-over-year, and declared a regular quarterly cash dividend of $0.17 per share.

Iradimed Corp’s Earnings Call Highlights Record Growth

The recent earnings call for Iradimed Corp painted an optimistic picture, highlighting record revenues and strong earnings growth. The company celebrated the successful launch of a new product line, although it acknowledged some challenges, including a decline in international sales and potential operational inefficiencies. Despite these hurdles, the overall sentiment was positive, with a clear trajectory for growth.